0001193125-26-067065
SEC filingRevenue growth of 54% YoY driven by new patient starts and PBP channel mix shift, with gross margin stable at 55%.
Beta Bionics, Inc. is a commercial-stage medical device company that designs, develops, and commercializes solutions for insulin-requiring people with diabetes. Its product, the iLet Bionic Pancreas, was cleared by the FDA in May 2023 for Type 1 diabetes in adults and children aged six and older, and was commercially launched that same month. As of December 31, 2025, the installed base reached 35,011 iLets.
The Business section does not disclose any reporting segments; the company operates as a single segment focused on the iLet platform and future product candidates.
The iLet is the only commercialized product. It is an automated insulin delivery system that uses adaptive closed-loop algorithms to determine and deliver 100% of insulin doses without requiring carbohydrate counting. The system integrates with DexCom G6/G7 or Abbott FreeStyle Libre 3 Plus CGMs. The company is developing Mint, a tubeless patch pump expected to launch by end of 2027, and a bihormonal iLet system that delivers both insulin and glucagon. A glucagon product candidate is being developed in collaboration with Xeris Pharmaceuticals.
The iLet is marketed and distributed in the United States through a direct commercial organization comprising sales, clinical, and customer support teams. When not contracted with a specific health plan, independent distributors are used for order processing and benefits investigation. The company targets high-volume endocrinology practices initially, with plans to expand to primary care. No key customer concentration is disclosed.
The insulin pump market is intensely competitive. Named competitors include Medtronic, Tandem, and Insulet. The iLet differentiates by being initialized with only body weight, not requiring carb counting, and offering a pharmacy benefit plan channel. However, competitors have greater resources, established relationships, and additional features (e.g., Insulet's patch form factor). Other competition includes insulin syringes, pens, and inhalable insulin.
The company's strategy focuses on driving adoption through targeted commercialization, superior customer support, and operational efficiency. It aims to expand into primary care and develop next-generation products: Mint (patch pump) and the bihormonal iLet. It also intends to pursue an expanded indication for Type 2 diabetes, which represents a significant long-term opportunity.
As of December 31, 2025, Beta Bionics had 420 full-time and 3 part-time employees. None are unionized. Employees receive benefits including company-matching 401(k) contributions, equity incentive programs, and fully paid health insurance premiums for employees and their families.
For the year ended December 31, 2025, Beta Bionics reported net sales of $100.3 million, a 54% increase from $65.1 million in 2024. The growth was primarily volume-driven, reflecting a 52% increase in new patient starts to 19,713 (from 12,994) and an expanding installed customer base (35,011 vs. 15,298). Single-use products accounted for 47% of net sales, up from 25%, indicating deepening recurring revenue. Gross profit rose 55% to $55.5 million, with gross margin stable at 55% as improved manufacturing cost absorption offset the dilutive effect of a shift toward the PBP channel (24% of net sales vs. 10%). Operating expenses increased 57% to $127.2 million, outpacing revenue growth, driven by a 66% rise in sales and marketing ($61.4 million) from headcount expansion and a 74% increase in G&A ($31.0 million) from public company costs. Net loss widened 34% to $73.2 million, though adjusted EBITDA improved sequentially from -$15.5 million in Q1 to -$10.5 million in Q4, reflecting operating leverage.
The company operates through two reimbursement channels: DME and PBP. DME channel sales represented 76% of net sales in 2025 (down from 90% in 2024), while PBP channel sales grew to 24% (from 10%). The PBP channel, which provides lower upfront revenue but higher lifetime value per patient, is a strategic priority. PBP-reimbursed new patient starts rose from high-single digits in 2024 to high-twenties in 2025, with Q4 2025 reaching low-30% of new starts. The PBP channel initially generates negative gross margin but turns cumulative positive after three months of supplies purchases. The mix shift toward PBP is expected to improve long-term economics despite near-term margin pressure.
Management expects operating expenses to increase significantly as it invests in R&D (patch pump, bihormonal system, T2D indication), sales force expansion, and public company infrastructure. The company believes existing cash, equivalents, and investments of $264.7 million, plus product revenue, will fund operations for at least 12 months. Key strategic priorities include expanding PBP channel coverage, growing the installed base, and advancing pipeline products. Seasonality is expected to cause lower Q1 sales due to insurance deductible resets. No specific revenue or margin guidance was provided.
As of December 31, 2025, Beta Bionics holds $31.6 million in cash and cash equivalents, $187.5 million in short-term investments (U.S. Treasury bills), and $45.4 million in long-term investments (U.S. Treasury notes), for a total liquidity of $264.5 million. The company has no debt; total liabilities are $41.1 million, consisting primarily of operating lease liabilities ($7.3 million), deferred revenue ($4.9 million), and accrued expenses ($22.4 million). Shareholders' equity stands at $287.6 million, reflecting the January 2025 IPO and private placement. Inventory increased to $21.7 million, up from $13.3 million, driven by commercial expansion.
The company has non-cancellable operating lease obligations of $8.8 million, with $2.0 million due within one year. Under the Xeris collaboration, the company expects to incur $1.1 million in remaining development and manufacturing costs as of December 31, 2025. Additionally, the company has a product warranty liability of $3.2 million and deferred revenue of $4.9 million related to software updates and mobile app access. No significant purchase commitments for raw materials or inventory were disclosed.
Capital expenditures totaled $5.3 million in 2025, primarily for manufacturing equipment and construction in progress, representing 5.3% of net sales. The company did not repurchase shares, pay dividends, or issue or repay debt during the period. Post-IPO, the company has no warrant liabilities remaining.
The company operates as a single segment. Revenue is disaggregated by product category (iLet pump and single-use supplies) and reimbursement channel (DME and PBP). In 2025, DME channel accounted for 75.6% of net sales ($75.8 million) and PBP for 24.4% ($24.4 million). Single-use product sales grew significantly, reflecting increased patient adoption. No international revenue was reported.
Beta Bionics has a limited commercial history, having launched its only product, the iLet, in May 2023. The company has incurred significant operating losses since inception, with net losses of $73.2 million in 2025 and an accumulated deficit of $369.9 million. Revenue is entirely dependent on the iLet and its single-use products, and the top four DME distributors account for approximately 52% of total sales, creating customer concentration risk. The company expects to continue incurring losses and may need additional capital beyond its current $219.2 million in cash and investments, which are estimated to fund operations through the first half of 2028.
The iLet is subject to a mandatory FDA post-market surveillance order (Section 522) requiring a 1,875-user study with a final report due June 2027. Failure to comply could result in revocation of 510(k) clearance. The company is also pursuing regulatory clearance for a bihormonal system (insulin + glucagon) and for Type 2 diabetes, which will require additional clinical trials and FDA approvals. The glucagon product candidate is being developed under a 505(b)(2) pathway, which carries uncertainty. Changes in FDA funding or staffing could delay reviews.
Beta Bionics relies on single-source suppliers for key components, including infusion sets (Unomedical), cartridge connectors (PMC), pump motors (Maxon), and boards (Matrix). The company manufactures at a single facility in Irvine, California, which is vulnerable to natural disasters or operational disruptions. Past manufacturing issues, such as screen breakage, have been addressed but could recur. The company also faces significant tariff exposure on components sourced from China, with current exemptions under the Nairobi Protocol subject to change. Cost increases from tariffs cannot be easily passed to customers due to multi-year pricing contracts.
The insulin pump market is intensely competitive, with well-capitalized rivals like Medtronic, Tandem, and Insulet. The iLet's unique features (no carb counting, body weight initialization) may not sustain a competitive advantage. Market acceptance depends on educating patients and healthcare providers, and any safety or efficacy concerns could severely impact sales. The company's multi-channel DME and PBP reimbursement strategy is unproven, and recent CMS rule changes could reduce reimbursement levels.
The iLet's software and mobile app present cybersecurity vulnerabilities; the FDA has warned about potential hacking risks. The company has experienced phishing attempts and expects continued threats. Additionally, the company must scale its organization (420 employees as of Dec 2025) and manage growth in sales, manufacturing, and regulatory functions, which could strain management and operations.
The provided document excerpt does not include the cash flow statement. Only the audit report, balance sheet, and income statement for Beta Bionics, Inc. were provided. Therefore, no cash flow analysis can be performed.